Universe Pharmaceuticals Inc.
UPCHealthcare|Drug Manufacturers - Specialty & Generic|CN
$1.39
-0.01 (-0.71%)
DCF Value
$7243.81
Tangible Book / Share
$98.23
Cash / Share
$51.57
Financials
Financial Snapshot
Market Cap
$878.1K
Enterprise Value
-$17.1M
Revenue (TTM)
$37.0M
Net Income (TTM)
-$852.7K
Cash & Investments
$29.0M
Net Cash
$19.5M
Free Cash Flow (TTM)
-$17.3M
Operating CF (TTM)
-$16.4M
Debt/Equity
0.17
Cash Runway & Burn Rate
Cash on Hand
$29.0M
Quarterly Burn
$4.1M
Monthly Burn
$1.4M
Est. Runway
~7.1 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.2M | $3.2M | $10.1M | $21.8M | $18.9M | $18.5M | $29.5M | $33.6M | $29.0M | |
| Operating Cash Flow | $4.5M | $13.2M | $6.1M | -$2.1M | -$1.3M | $1.1M | -$9.5M | -$5.1M | -$16.4M | |
| Free Cash Flow | $4.3M | $13.1M | $6.1M | -$15.6M | -$1.4M | $1.1M | -$9.9M | -$5.4M | -$17.3M | |
| Capital Expenditure | -$145.1K | -$86.3K | -$51.8K | -$13.5M | -$93.7K | -$44.2K | -$363.1K | -$347.2K | -$873.2K | |
| Financing Cash Flow | -$4.9M | -$16.0M | $470.1K | $26.6M | $3.3M | -$1.4M | $34.0M | $9.7M | $37.5M |
R&D Spending
R&D (TTM)
$3.7M
R&D Intensity
10.0%
R&D Growth vs Prior
+453.0%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $33.2M | $30.7M | $48.0M | $40.1M | $32.3M | $23.0M | $17.9M | $37.0M | |
| R&D Expense | $789.4K | $618.4K | $583.1K | $5.5M | $7.6M | $4.9M | $3.0M | $671.8K | $3.7M | |
| R&D % of Revenue | 2.8% | 1.9% | 1.9% | 11.4% | 19.0% | 15.0% | 13.2% | 3.8% | 10.0% | |
| SG&A | $2.4M | $2.3M | $2.8M | $6.3M | $21.3M | $9.0M | $10.4M | $8.0M | $18.8M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $33.2M | $30.7M | $48.0M | $40.1M | $32.3M | $23.0M | $17.9M | $37.0M | |
| Cost of Revenue | $15.1M | $19.8M | $16.6M | $22.7M | $18.3M | $22.0M | $17.0M | $11.6M | $24.7M | |
| Gross Profit | $13.4M | $13.4M | $14.1M | $25.3M | $21.9M | $10.3M | $6.1M | $6.3M | $12.4M | |
| R&D | $789.4K | $618.4K | $583.1K | $5.5M | $7.6M | $4.9M | $3.0M | $671.8K | $3.7M | |
| SG&A | $2.4M | $2.3M | $2.8M | $6.3M | $21.3M | $9.0M | $10.4M | $8.0M | $18.8M | |
| Operating Income | $9.7M | $9.8M | $10.3M | $13.6M | -$7.0M | -$3.5M | -$8.0M | -$2.9M | -$10.7M | |
| Interest Expense | $164.9K | $129.3K | $123.8K | $101.6K | $162.4K | $156.8K | $278.2K | $232.0K | $499.8K | |
| Pretax Income | $9.5M | $9.7M | $10.1M | $13.6M | -$8.0M | -$3.9M | -$8.1M | -$3.7M | -$911.2K | |
| Net Income | $7.6M | $7.6M | $7.6M | $11.3M | -$8.7M | -$6.2M | -$8.7M | -$3.7M | -$852.7K | |
| EPS (Diluted) | 1303.36 | 1294.54 | 1295.70 | 2147.18 | -1475.02 | -1040.53 | -1436.12 | -1055.75 | -228.06 | |
| EBITDA | $10.1M | $10.2M | $10.6M | $14.2M | -$6.4M | -$3.2M | -$7.4M | -$2.9M | $502.7K | |
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.56 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.2M | $3.2M | $10.1M | $8.1M | $5.7M | $5.3M | $29.5M | $33.6M | $27.6M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $13.7M | $13.1M | $13.2M | $0.00 | $0.00 | $1.5M | |
| Total Current Assets | $22.0M | $12.2M | $22.8M | $50.5M | $41.5M | $36.8M | $51.6M | $53.6M | $55.2M | |
| Total Assets | $28.1M | $17.8M | $28.8M | $70.1M | $59.5M | $53.3M | $68.0M | $69.3M | $71.5M | |
| Total Current Liabilities | $18.4M | $5.5M | $8.0M | $11.2M | $13.1M | $13.8M | $20.3M | $13.2M | $13.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.1M | $0.00 | $2.2M | |
| Total Liabilities | $18.4M | $5.5M | $8.0M | $11.2M | $13.1M | $13.8M | $22.5M | $13.2M | $15.8M | |
| Stockholders' Equity | $9.7M | $12.4M | $20.8M | $58.9M | $46.4M | $39.5M | $45.5M | $56.1M | $55.6M | |
| Retained Earnings | $2.8M | $6.2M | $13.7M | $25.1M | $16.3M | $10.2M | -$10.2M | -$13.8M | -$15.4M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.5M | $13.2M | $6.1M | -$2.1M | -$1.3M | $1.1M | -$9.5M | -$5.1M | -$16.4M | |
| Capital Expenditure | -$145.1K | -$86.3K | -$51.8K | -$13.5M | -$93.7K | -$44.2K | -$363.1K | -$347.2K | -$873.2K | |
| Free Cash Flow | $4.3M | $13.1M | $6.1M | -$15.6M | -$1.4M | $1.1M | -$9.9M | -$5.4M | -$17.3M | |
| Investing Cash Flow | -$145.1K | -$86.0K | -$51.8K | -$27.1M | -$3.9M | -$44.2K | -$361.3K | -$341.8K | -$2.4M | |
| Financing Cash Flow | -$4.9M | -$16.0M | $470.1K | $26.6M | $3.3M | -$1.4M | $34.0M | $9.7M | $37.5M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $28.8M | $0.00 | $0.00 | $25.0M | $15.0M | $40.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$1.9M | $1.1K | $911.2K | $624.4K | $3.3M | -$1.4M | $9.0M | -$5.3M | $3.5M | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | -$793.2K | -$3.0M | $6.9M | -$2.0M | -$2.4M | -$426.2K | $24.2M | $4.1M | $18.7M |
Dilution Tracker
Shares Outstanding
1M
5-Year Share Growth
-40.4%
Stock Issuance (TTM)
$40.0M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.56 | |
| Change vs Prior % | — | 0.0% | 0.0% | -9.6% | 12.3% | 0.0% | 2.6% | -42.8% | 16097.2% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $28.8M | $0.00 | $0.00 | $25.0M | $15.0M | $40.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 47.0% | 40.3% | 45.9% | 52.8% | 54.5% | 31.9% | 26.4% | 35.3% | 33.4% | |
| Operating Margin % | 33.9% | 29.4% | 33.4% | 28.3% | -17.5% | -10.9% | -34.8% | -16.3% | -28.9% | |
| Net Margin % | 26.7% | 22.7% | 24.6% | 23.6% | -21.8% | -19.1% | -37.9% | -20.6% | -2.3% | |
| EBITDA Margin % | 35.5% | 30.6% | 34.6% | 29.6% | -15.9% | -9.9% | -32.0% | -16.4% | 1.4% | |
| FCF Margin % | 15.1% | 39.5% | 19.7% | -32.5% | -3.5% | 3.3% | -42.9% | -30.2% | -46.7% | |
| ROE % | 78.5% | 61.0% | 36.3% | 19.2% | -18.8% | -15.6% | -19.2% | -6.5% | -3.5% | |
| ROA % | 27.1% | 42.3% | 26.2% | 16.1% | -14.7% | -11.6% | -12.8% | -5.3% | -2.7% | |
| ROIC % | 62.7% | 51.2% | 33.3% | 17.8% | -13.9% | -7.8% | -15.0% | -4.5% | -3.2% | |
| R&D / Revenue % | 2.8% | 1.9% | 1.9% | 11.4% | 19.0% | 15.0% | 13.2% | 3.8% | 10.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 16.5% | -7.6% | 56.3% | -16.3% | -19.5% | -28.7% | -22.4% | |
| Gross Profit | 0.0% | -0.0% | 5.1% | 79.7% | -13.6% | -52.9% | -41.1% | 3.8% | |
| Operating Income | 0.0% | 1.0% | 5.1% | 32.6% | -151.7% | 49.8% | -127.4% | 63.6% | |
| Net Income | 0.0% | -0.7% | 0.1% | 49.8% | -177.2% | 29.5% | -41.6% | 57.9% | |
| EPS (Diluted) | 0.0% | -0.7% | 0.1% | 65.7% | -168.7% | 29.5% | -38.0% | 26.5% | |
| Operating Cash Flow | 0.0% | 196.3% | -53.7% | -133.6% | 36.2% | 185.3% | -948.7% | 46.9% | |
| Free Cash Flow | 0.0% | 204.3% | -53.8% | -357.1% | 91.0% | 176.5% | -1017.3% | 45.3% | |
| R&D Expense | 0.0% | -21.7% | -5.7% | 837.3% | 39.5% | -36.3% | -37.6% | -77.8% | |
| SG&A Expense | 0.0% | -3.9% | 21.9% | 124.3% | 239.6% | -57.7% | 16.0% | -23.4% | |
| Total Assets | 0.0% | -36.5% | 61.5% | 143.5% | -15.1% | -10.5% | 27.5% | 2.0% | |
| Book Value / Share | 0.0% | 27.9% | 68.0% | 213.4% | -29.9% | -14.9% | 12.2% | 115.5% | |
| Debt | 0.0% | -3.8% | 4.9% | 63.8% | -9.2% | 39.3% | 45.8% | 15.8% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -9.6% | 12.3% | 0.0% | 2.6% | -42.8% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High4.14 / 13.20 / 13.21
P/S0.05
10Y Low / Med / High0.00 / 0.98 / 3.50
P/B0.01
10Y Low / Med / High0.00 / 0.80 / 10.30
EV/EBITDA13.12
10Y Low / Med / High2.80 / 8.70 / 9.74
EV/Revenue-0.97
10Y Low / Med / High0.11 / 2.98 / 3.37
P/FCFAt Loss
10Y Low / Med / High3.14 / 16.45 / 23.14
Intrinsic Value Models (per share)
DCF Value
$7243.81
Tangible Book / Share
$98.23
Net Current Assets / Share
$62.35
Graham Net-Net
$54.26
Cash / Share
$51.57
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 13.12 | 13.21 | 13.20 | 4.14 | -1.38 | -0.55 | -0.10 | -0.00 | -0.40 | |
| P/S Ratio | 3.50 | 3.00 | 3.25 | 0.98 | 0.30 | 0.10 | 0.04 | 0.00 | 0.05 | |
| P/B Ratio | 10.30 | 8.05 | 4.79 | 0.80 | 0.26 | 0.09 | 0.02 | 0.00 | 0.01 | |
| EV/EBITDA | 9.51 | 9.74 | 8.70 | 3.04 | -1.61 | -1.12 | 2.80 | 8.32 | 13.12 | |
| EV/Revenue | 3.37 | 2.98 | 3.01 | 0.90 | 0.26 | 0.11 | -0.90 | -1.36 | -0.97 |
Analyst Estimates & Quality
Altman Z-Score
0.60
Distress
Piotroski F-Score
2
Weak